T Cell therapy for solid tumors with specific KRAS and HLA types
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a personalized immune cell treatment made for people with advanced solid cancers that have not responded to standard care. It’s designed for tumors carrying a specific KRAS mutation (G12V or G12D) and for people whose immune “HLA type” matches the therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years.
- You have advanced solid cancer confirmed by biopsy or body fluid test, and standard treatments have failed (or you can’t get them).
- Your tumor (or blood test) shows a KRAS G12V or G12D mutation, and your HLA type matches the therapy.
- You can be expected to live more than 3 months, and your overall health score is 0–2.
- Your cancer can be measured on scans (at least one measurable lesion).
- Your blood counts and organ tests (kidney, liver, clotting) are within required ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a custom immune-cell treatment made from your blood that targets the KRAS G12V change in certain cancers. It is for people with advanced cancer who have already tried standard treatments, and it may help your immune system recognize and attack tumor cells.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This trial tests a new cell therapy, DCTY1102, for people with advanced solid tumors like pancreatic, colorectal, or lung cancer who have tried other treatments. It uses your own immune cells that are modified to target a specific genetic change in your tumor.
This trial tests a new cell therapy (TCR-T) designed to target KRAS mutations in advanced cancers. It is for people whose standard treatments have stopped working.
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
This trial tests a new type of immune cell therapy called TCR-T that targets a specific genetic change (KRAS mutation) found in some pancreatic, colorectal, and lung cancers. If you have the right genetic markers and previous treatments haven't worked, this study may offer a new option.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.